

Purpose:
Early administration of beneficial bacteria that promote immune tolerance represents a novel approach for the prevention and treatment of allergic diseases, such as atopic dermatitis and asthma. STMC-103H is a live biotherapeutic product (LBP) containing a consortium of intestinal bacteria that may impact the incidence of allergic sensitization and disease in neonates and infants at risk for developing allergy and asthma. STMC-103H is an oral capsule containing powder which will be mixed with a small amount of breastmilk, the participant’s formula, or a milk product. Siolta Therapeutics is testing this investigational drug for the prevention of allergic diseases, including atopic dermatitis (eczema), food allergy, asthma, and allergic rhinitis (hay fever).





The prescreener preview is complete. You may now close the preview.
